These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 822331)

  • 1. The swine-influenza decision.
    Schoenbaum SC; McNeil BJ; Kavet J
    N Engl J Med; 1976 Sep; 295(14):759-65. PubMed ID: 822331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishing the health and economic impact of influenza vaccination within the European Union 25 countries.
    Ryan J; Zoellner Y; Gradl B; Palache B; Medema J
    Vaccine; 2006 Nov; 24(47-48):6812-22. PubMed ID: 17034909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Managing public health risks: the swine flu immunization program revisited.
    Fielding JE
    Am J Law Med; 1978; 4(1):35-43. PubMed ID: 685984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of a universal influenza vaccination program for adults aged 50-64 years in Australia.
    Newall AT; Scuffham PA; Kelly H; Harsley S; Macintyre CR
    Vaccine; 2008 Apr; 26(17):2142-53. PubMed ID: 18343537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing influenza vaccine distribution.
    Medlock J; Galvani AP
    Science; 2009 Sep; 325(5948):1705-8. PubMed ID: 19696313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination against pandemic influenza A/H1N1v in England: a real-time economic evaluation.
    Baguelin M; Hoek AJ; Jit M; Flasche S; White PJ; Edmunds WJ
    Vaccine; 2010 Mar; 28(12):2370-84. PubMed ID: 20096762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influenza vaccination of recommended adult populations, U.S., 1989-2005.
    Lu P; Bridges CB; Euler GL; Singleton JA
    Vaccine; 2008 Mar; 26(14):1786-93. PubMed ID: 18336965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of clinical case definitions with differing levels of sensitivity and specificity on estimates of the relative and absolute health benefits of influenza vaccination among healthy working adults and implications for economic analyses.
    Nichol KL; Mendelman P
    Virus Res; 2004 Jul; 103(1-2):3-8. PubMed ID: 15163481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using the National Health Interview Survey: time trends in influenza vaccinations among targeted adults.
    Pleis JR; Gentleman JF
    Eff Clin Pract; 2002; 5(3 Suppl):E3. PubMed ID: 12166924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Could a federal program to promote influenza vaccination among elders be cost-effective?
    Patel MS; Davis MM
    Prev Med; 2006 Mar; 42(3):240-6. PubMed ID: 16480761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A worksite influenza immunization program. Impact on lost work days, health care utilization, and health care spending.
    Dille JH
    AAOHN J; 1999 Jul; 47(7):301-9. PubMed ID: 10661043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effectiveness of vaccination against influenza in healthy, working adults.
    Nichol KL; Lind A; Margolis KL; Murdoch M; McFadden R; Hauge M; Magnan S; Drake M
    N Engl J Med; 1995 Oct; 333(14):889-93. PubMed ID: 7666874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influenza vaccination coverage rates in 5 European countries: a population-based cross-sectional analysis of the seasons 02/03, 03/04 and 04/05.
    Müller D; Szucs TD
    Infection; 2007 Oct; 35(5):308-19. PubMed ID: 17885730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older.
    Maciosek MV; Solberg LI; Coffield AB; Edwards NM; Goodman MJ
    Am J Prev Med; 2006 Jul; 31(1):72-9. PubMed ID: 16777545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits and costs of immunizing children against influenza at school: an economic analysis based on a large-cluster controlled clinical trial.
    Schmier J; Li S; King JC; Nichol K; Mahadevia PJ
    Health Aff (Millwood); 2008; 27(2):w96-104. PubMed ID: 18216044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of oral cholera vaccine in a stable refugee population at risk for epidemic cholera and in a population with endemic cholera.
    Murray J; McFarland DA; Waldman RJ
    Bull World Health Organ; 1998; 76(4):343-52. PubMed ID: 9803585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical evaluation of neuraminidase monospecific (HEqN2) recombinant influenza vaccine in children.
    Beutner KR; Rizzone C; DeMello S; Ogra PL
    Dev Biol Stand; 1976; 33():162-70. PubMed ID: 782964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States.
    Luce BR; Nichol KL; Belshe RB; Frick KD; Li SX; Boscoe A; Rousculp MD; Mahadevia PJ
    Vaccine; 2008 Jun; 26(23):2841-8. PubMed ID: 18462851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling the health-economic impact of the next influenza pandemic in The Netherlands.
    Hak E; Meijboom MJ; Buskens E
    Vaccine; 2006 Nov; 24(44-46):6756-60. PubMed ID: 16797797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prophylactic influenza vaccination: what is the situation in Germany?].
    Wutzler P
    Dtsch Med Wochenschr; 2006 Mar; 131(9):453-7. PubMed ID: 16493571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.